188 related articles for article (PubMed ID: 11772248)
1. The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent.
Rodrigues CM; Steer CJ
Expert Opin Investig Drugs; 2001 Jul; 10(7):1243-53. PubMed ID: 11772248
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
Roma MG; Toledo FD; Boaglio AC; Basiglio CL; Crocenzi FA; Sánchez Pozzi EJ
Clin Sci (Lond); 2011 Dec; 121(12):523-44. PubMed ID: 21854363
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
[TBL] [Abstract][Full Text] [Related]
4. Bile acids: regulation of apoptosis by ursodeoxycholic acid.
Amaral JD; Viana RJ; Ramalho RM; Steer CJ; Rodrigues CM
J Lipid Res; 2009 Sep; 50(9):1721-34. PubMed ID: 19417220
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress.
Serviddio G; Pereda J; Pallardó FV; Carretero J; Borras C; Cutrin J; Vendemiale G; Poli G; Viña J; Sastre J
Hepatology; 2004 Mar; 39(3):711-20. PubMed ID: 14999689
[TBL] [Abstract][Full Text] [Related]
6. [Ursodeoxycholic acid in the treatment of cholestatic liver diseases].
Arrese M; Accatino L
Rev Med Chil; 1993 Apr; 121(4):439-46. PubMed ID: 8272619
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children.
Poupon R; Poupon RE
Pharmacol Ther; 1995 Apr; 66(1):1-15. PubMed ID: 7630925
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats.
Purucker E; Marschall HU; Winograd R; Matern S
Biochim Biophys Acta; 2001 Apr; 1526(1):44-52. PubMed ID: 11287121
[TBL] [Abstract][Full Text] [Related]
9. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
10. Ileal absorption of bile acids in patients with chronic cholestasis: SeHCAT test results and effect of ursodeoxycholic acid (UDCA).
Chazouillères O; Marteau P; Haniche M; Jian R; Poupon R
Dig Dis Sci; 1996 Dec; 41(12):2417-22. PubMed ID: 9011452
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic liver disease with ursodeoxycholic acid.
Guslandi M
J Int Med Res; 1990; 18(6):497-505. PubMed ID: 2292332
[TBL] [Abstract][Full Text] [Related]
12. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U
J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholic acid (UDCA) in the treatment of chronic cholestatic diseases.
Calmus Y; Poupon R
Biochimie; 1991 Oct; 73(10):1335-8. PubMed ID: 1782227
[TBL] [Abstract][Full Text] [Related]
14. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
15. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G; Beuers U
Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
[TBL] [Abstract][Full Text] [Related]
16. Modulation of hepatocyte apoptosis: cross-talk between bile acids and nuclear steroid receptors.
Solá S; Amaral JD; Aranha MM; Steer CJ; Rodrigues CM
Curr Med Chem; 2006; 13(25):3039-51. PubMed ID: 17073645
[TBL] [Abstract][Full Text] [Related]
17. Omega-3 Polyunsaturated Fatty Acid: A Pharmaco-Nutraceutical Approach to Improve the Responsiveness to Ursodeoxycholic Acid.
Thérien A; Cieślak A; Verreault M; Perreault M; Trottier J; Gobeil S; Vohl MC; Barbier O
Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444777
[TBL] [Abstract][Full Text] [Related]
18. 3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17alpha-ethynyl-estradiol-induced cholestasis in rats.
Clerici C; Castellani D; Asciutti S; Pellicciari R; Setchell KD; O'Connell NC; Sadeghpour B; Camaioni E; Fiorucci S; Renga B; Nardi E; Sabatino G; Clementi M; Giuliano V; Baldoni M; Orlandi S; Mazzocchi A; Morelli A; Morelli O
Toxicol Appl Pharmacol; 2006 Jul; 214(2):199-208. PubMed ID: 16487557
[TBL] [Abstract][Full Text] [Related]
19. New therapeutical indications of ursodeoxycholic acid.
Copaci I; Micu L; Iliescu L; Voiculescu M
Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]